Asthma and eosinophilia as predictors of outcomes in COVID-19 disease

Identification: Chinthrajah-R. Sharon


Asthma and eosinophilia as predictors of outcomes in COVID-19 disease
William Collins MD*1,2, Ziyuan He PhD1, Lauren Eggert, MD3, Allie Lee1, Shu Cao1, Gopal Dhondalay PhD1, Tina Sindher MD1, Kari C Nadeau MD PhD1, R. Sharon Chinthrajah, MD1,3 
1Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, 2Department of Medicine, Division of Hospital Medicine, Stanford University School of Medicine, 3Department of Medicine, Division of Pulmonary, Allergy & Critical Care Medicine, Stanford University School of Medicine; *corresponding author
Rationale: There has been conflicting initial data regarding the effect of comorbid asthma on severity of illness with COVID-19 disease. Multiple studies have demonstrated an increased prevalence of asthma among hospitalized patients, but more recent studies have not shown an increased risk of severe infection in patients with asthma. Furthermore, the Th2 inflammation associated with the allergic asthma subtype can downregulate ACE-2 expression providing a potential protective effect. Our objective is to understand the impact of asthma and eosinophilia as predictors of disease outcomes in patients at Stanford Hospital infected with SARS-CoV-2  

Methods:  SARS-CoV-2 RT-PCR positive patients tested at Stanford Hospital were identified and hospitalization status, asthma history, demographics, co-existing conditions, laboratory values and COVID-19 severity were determined.  Inpatients were defined as those patients hospitalized within 14 days of a positive test for SARS-CoV-2. Patients were excluded from further analysis if they had no other documented clinical history or were younger than 28 days. COVID-19 disease severity was designated according to the 5-point NIH COVID-19 treatment guidelines.
Results:  From March 2 to September 30, 2020, 168,190 patients were tested for SARS-CoV-2 at Stanford Hospital and 6,976 (4.1%) tested positive. 1,380 patients were excluded from further analysis. Of the remaining 5,596 patients, 605 required hospitalization. Of the 605 hospitalized patients, 100 had a pre-existing diagnosis of asthma. History of asthma was significantly associated with COVID-19-related hospitalization (p<0.001, adjusted odds ratio = 1.52, 95%CI = [1.185-1.933]) in multivariate analysis adjusted for age, sex, and ethnicity. Additionally, older age, male sex, obesity (BMI>30) and asthma were significantly associated with clinical severity of COVID-19 in hospitalized patients in multivariate analysis (p<0.05). 801 SARS-CoV-2+ patients had historical eosinophil counts (HEC) available for analysis, and lower HEC was significantly associated with need for hospitalization when adjusted for both age and asthma status.    
Conclusions: In our cohort of patients tested for SARS-CoV-2 at Stanford, 605 were hospitalized at Stanford Hospital. Older age, male sex, obesity, and asthma were significantly associated with increased clinical severity of COVID-19 disease in hospitalized patients. Additionally, asthma and lower historical eosinophil counts were associated with need for hospitalization in certain sub-groups. Larger cohorts are needed to understand which factors in asthmatic patients contribute to more severe COVID-19 infection.



Credits: None available.

You must be logged in and own this product in order to post comments.